Company intelligence / Profile preview

ExcellaBio

Ownership: Private
Development stage: Other

Overview

ExcellaBio has developed a patented process for manufacturing synthetic exosomes ("Bioxomes") that enables uniform particle size and scalable production. These Bioxomes mimic natural extracellular vesicles by delivering intracellular cargo such as nucleic acids or proteins into target cells. The technology aims to unlock new cell/gene therapy applications by providing safer alternatives to whole-cell therapies. No direct clinical results have been published yet—current status appears preclinical/platform-focused.

Therapeutic areas: GastroenterologyNeurologyDermatology
Modalities: Extracellular vesicle-based therapySynthetic exosome-based delivery systems ("Bioxomes")
Industry: Biotech

Drug pipeline

1 asset

autologous natural killer cells

Partnerships

Orgenesis Inc.—collaboration/licensing agreement for commercializing the Bioxome™ technology globally.

Beyond the preview

Go deeper on ExcellaBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ExcellaBio.

Explore the full profile